Translational pipeline for high-throughput wound healing discovery
An integrated platform that accelerates wound healing discovery by combining high-throughput screening with human-relevant validation. It utilizes automated assays and ex vivo skin models for comprehensive testing of biologics, biomaterials, and therapeutic devices.
Overview
iFyber presents a cutting-edge translational pipeline designed to expedite the discovery of wound-healing and tissue-regeneration strategies. This innovative platform combines high-throughput screening with human-relevant validation, offering a comprehensive solution to bridge the gap between scalable screening and clinical relevance. By utilizing automated multi-well scratch assays with human keratinocytes and fibroblasts, the platform quantifies migration and wound closure kinetics efficiently. Top candidates are further evaluated using a full-thickness ex vivo human skin wound model, assessing critical parameters like re-epithelialization, tissue architecture, and cytokine release.
Technical specifications
Key features:
- High-throughput scratch assays with automated imaging and quantitative analysis
- Ex vivo human skin wound model for advanced validation
- Integrated LC-MS/MS for quantitative biodistribution and mechanistic analysis
- Supports testing of a range of therapeutics including biologics, biomaterials, implants, and advanced therapeutic devices
- Consistent quantitative endpoints for enhanced prediction of clinical performance
Technology readiness level
Currently at TRL 4, the platform has undergone validation in human keratinocyte/fibroblast assays, ex vivo skin models, and LC-MS/MS analyses. Future phases aim to optimize scratch assays, integrate skin wound models, and incorporate LC-MS/MS for comprehensive analysis, with pilot studies to demonstrate robustness and translational value.
About iFyber
iFyber is a preclinical contract research organization (CRO) that provides specialized research and development services at the intersection of chemistry, biology, and materials science. The company serves industries including medical devices, wound care, diagnostics, and specialty textiles. Unlike traditional testing labs that perform commoditized assays, iFyber operates as an extension of client R&D teams by providing custom method development, experimental design, and consultative support. Its technical capabilities include microbial control, virology, analytical chemistry, and cell and tissue culture, all supported by a multidisciplinary team of scientists, many of whom hold advanced degrees. The firm leverages a high-touch, collaborative service model to solve complex challenges, ranging from exploratory conceptual evaluations to full-scale validation testing.
By integrating directly with client teams, iFyber helps accelerate development timelines, increase cost-effectiveness, and enhance competitive advantages for innovators. The company supports projects across various stages, from initial proof-of-concept to regulatory submission, ensuring that studies are aligned with intended clinical use and potential regulatory pathways. Their engagement is built on a fee-for-service model that preserves client intellectual property rights. Through state-of-the-art instrumentation and custom-designed experimental models, iFyber delivers reliable, actionable data that assists companies in navigating technical hurdles and advancing new technologies from the laboratory to the market.
delivered to your inbox.